Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.

A massive disconnect exists where scientific breakthroughs are accelerating, yet the biotech market is in a downturn, with many companies trading below cash. This paradox highlights structural and economic failures within the industry, rather than a lack of scientific progress. The core question is why the business is collapsing while the technology is exploding.

MIT Professor Jim Collins estimates a $20 billion investment could fund the R&D and clinical trials for 15-20 new antibiotics, solving the crisis for decades. This cost is a fraction of recent tech investments, framing an existential threat as a solvable, relatively affordable problem.

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.

Investment firms are actively de-investing from the entire rare disease sector—not just specific companies—due to perceived FDA unpredictability. This demonstrates that capital is highly fluid and will abandon entire therapeutic areas for more stable ones, showing how sector-wide regulatory risk can starve innovation even in high-need fields.

Even when AMR experts explain that the crisis could be deadlier than cancer, their own families dismiss it as an overreaction. This personal anecdote highlights the severe public awareness gap surrounding one of the world's most urgent health crises, even among those closest to the issue.